[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337726-105":59,"doc-detail-337726-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","blood-lead-level-as-marker-of-increased-risk-of-ovarian-cancer-in-brca1-carriers-research-findings","Blood Lead Level as Marker of Increased Risk of Ovarian Cancer in BRCA1 Carriers - research findings","","BRCA1 mutations substantially increase the risks of breast and ovarian cancer, and environmental or other modifiers may further shape individual risk. This study enrolled 989 BRCA1 mutation carriers from Pomeranian Medical University, Poland, measured blood lead levels by inductively coupled plasma mass spectrometry, and grouped participants by tertiles. Cox regression evaluated cancer risk associations. Elevated lead levels (>13.6 µg/L) correlated with higher ovarian cancer risk, with no significant association for breast cancer. Findings suggest preventive salpingo-oophorectomy prioritization and motivate lead-lowering and detoxification strategies, pending validation in diverse populations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/blood-lead-level-as-marker-of-increased-risk-of-ovarian-cancer-in-brca1-carriers-research-findings/337726/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/blood-lead-level-as-marker-of-increased-risk-of-ovarian-cancer-in-brca1-carriers-research-findings/337726.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the study address about lead exposure and BRCA1 carriers?","Question",{"text":112,"@type":113},"It examines whether blood lead level serves as a marker linked to increased ovarian cancer risk specifically in BRCA1 mutation carriers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were blood lead levels measured and categorized in the study?",{"text":117,"@type":113},"Blood lead levels were measured using inductively coupled plasma mass spectrometry, and participants were assigned to categories based on tertiles of blood lead.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings regarding ovarian and breast cancer risks?",{"text":121,"@type":113},"Higher blood lead levels (>13.6 µg/L) were associated with increased ovarian cancer risk, while no significant correlation was found with breast cancer risk.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337726,1790796444,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","nutrients   \nCommunication  \nBlood Lead Level as Marker of Increased Risk of Ovarian Cancer in BRCA1 Carriers  \nAdam Kilja ´nczyk 1, Milena Matuszczak 1, Wojciech Marciniak 2, Róa Derkacz 2, Klaudia Stempa 1,  \nPiotr Baszuk 1,2, Marta Bry´skiewicz 1,2, Krzysztof Lubi ´nski 1, Cezary Cybulski 1,2, Tadeusz D˛ebniak 1,2, Jacek Gronwald 1,2, Tomasz Huzarski 1,2,3, Marcin R. Lener 1, Anna Jakubowska 1, Marek Szwiec 4, Małgorzata Stawicka-Niełacna 3, Dariusz Godlewski 5, Artur Prusaczyk 6, Andrzej Jasiewicz 7, Tomasz Kluz 8, Joanna Tomiczek-Szwiec 9, Ewa Kilar-Kobierzycka 10, Monika Siołek 11, Rafał Wi´sniowski 12, Renata Posmyk 13, Joanna Jarkiewicz-Tretyn 14, Ping Sun 15, Rodney J. Scott 16, Steven A. Narod 15 and Jan Lubi ´nski 1,2, *  \nCitation: Kilja ´nczyk, A.; Matuszczak, M.; Marciniak, W.; Derkacz, R.; Stempa, K.; Baszuk, P.; Bry´skiewicz, M.; Lubi ´nski, K.; Cybulski, C.; D˛ebniak, T.; et al. Blood Lead Level as Marker of Increased Risk of Ovarian Cancer in BRCA1 Carriers. Nutrients 2024, 16, 1370. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/nu16091370](10.3390/nu16091370)  \nAcademic Editors: Manuel Bicho and Ana Valente  \nReceived: 26 March 2024  \nRevised: 26 April 2024  \nAccepted: 29 April 2024  \nPublished: 30 April 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; [adam.kiljanczyk@pum.edu.pl](adam.kiljanczyk@pum.edu.pl) (A.K.); [milena.matuszczak@pum.edu.pl](milena.matuszczak@pum.edu.pl) (M.M.); [piotr.baszuk@pum.edu.pl](piotr.baszuk@pum.edu.pl) (P.B.); [tadeusz.debniak@pum.edu.pl](tadeusz.debniak@pum.edu.pl) (T.D.)  \n2 Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra, Poland  \n3 Department of Clinical Genetics and Pathology, University of Zielona Góra, ul. Zyty 28, 65-046 Zielona Góra, Poland; [gosiastawicka33@gmail.com](gosiastawicka33@gmail.com)  \n4 Department of Surgery and Oncology, University of Zielona Góra, Zyty 28, 65-046 Zielona Góra, Poland  \n5 OPEN, Kazimierza Wielkiego 24 Str., 61-863 Pozna ´n, Poland  \n6 Medical and Diagnostic Center, Niklinowa 9, 08-110 Siedlce, Poland  \n7 Genetic Counseling Center, Subcarpatian Oncological Hospital, 18 Bielawskiego Str., 36-200 Brzozów, Poland  \n8 Department of Gynecology, Gynecology Oncology and Obstetrics, Institute of Medical Sciences, Medical College, Rzeszow University, Rejtana 16c, 35-959 Rzeszow, Poland  \n9 Department of Histology, Department of Biology and Genetics, Faculty of Medicine, University of Opole, 45-040 Opole, Poland  \n10 Department of Oncology, District Specialist Hospital, Le´sna 27-29 Str., 58-100 ´Swidnica, Poland  \n11 Holycross Cancer Center, Artwi ´nskiego 3 Str., 25-734 Kielce, Poland  \n12 Regional Oncology Hospital, Wyzwolenia 18 Str., 43-300 Bielsko Biała, Poland  \n13 Department of Clinical Genetics, Podlaskie Medical Center, 15-399 Bialystok, Poland  \n14 Non-Public Health Care Centre, Cancer Genetics Laboratory, 87-100 Toru ´n, Poland  \n15 Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto, ON M5G 1N8, Canada; [ping.sun@wchospital.ca](ping.sun@wchospital.ca) (P.S.)  \n16 Medical Genetics, Hunter Medical Research Institute, Priority Research Centre for Cancer Research, Innovation and Translation, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Pathology North, John Hunter Hospital, King and Auckland Streets, Newcastle, NSW 2300, Australia  \n* [Correspondence: jan.lubinski@pum.edu.pl](Correspondence: jan.lubinski@pum.edu.pl)  \nAbstract: BRCA1 mutations substan","cbCairJXH97e5y0o","https://ap.wps.com/l/cbCairJXH97e5y0o","pdf",961916,"English","# Introduction\n## Methods and measurements\n## Risk analysis and results\n## Discussion and implications","[{\"question\":\"What question does the study address about lead exposure and BRCA1 carriers?\",\"answer\":\"It examines whether blood lead level serves as a marker linked to increased ovarian cancer risk specifically in BRCA1 mutation carriers.\"},{\"question\":\"How were blood lead levels measured and categorized in the study?\",\"answer\":\"Blood lead levels were measured using inductively coupled plasma mass spectrometry, and participants were assigned to categories based on tertiles of blood lead.\"},{\"question\":\"What were the main findings regarding ovarian and breast cancer risks?\",\"answer\":\"Higher blood lead levels (\\u003e13.6 µg/L) were associated with increased ovarian cancer risk, while no significant correlation was found with breast cancer risk.\"}]","Blood Lead Level as Marker of Increased Risk of Ovarian Cancer in BRCA1 Carriers - research findings | PDF",1790020361,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97a57dc03c724711b8a8771e19848f62.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/40d99d675278b6969ac266c028e83dd8.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/659a26edab8f90e3134e1cefc7469521.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc4161ffb2bcc320c03a184e7335abfd.webp",980,1385]